Skip to main content
Parkinson's Research

Research News

Read the latest developments, reporting and analysis from the world of Parkinson's research, including progress made in studies, tools and collaborations funded by The Michael J. Fox Foundation.


  • Two researchers in a lab

    Trial Testing Dyskinesia Drug Moves Forward with Support from Global Parkinson’s Organizations

    The Michael J. Fox Foundation is collaborating with Parkinson’s UK to fund a Phase II clinical trial of a new drug called NLX-112 with biopharma company Neurolixis.

  • Default content image

    Foundation Confers Edmond J. Safra Humanitarian Award to Lily Safra and Honors Distinguished Scientists with 2020 Major Research Prizes

    The Foundation honored two researchers for their groundbreaking work in Parkinson's disease and dystonia research and announced a new humanitarian award on November 17, 2020.


  • What We Fund: $6 Million in New Grants for Parkinson’s Research

    Alzheimer’s Drug Aducanumab Back in the News

    An advisory panel recently recommended against approval of aducanumab, which aims to slow Alzheimer’s, citing lack of solid evidence. Now the FDA decides.

  • Breaking News: New Dyskinesia Drug Submitted to FDA

    News in Context: A Diabetes Drug for Parkinson’s?

    New research suggests that people with diabetes who take exenatide, a drug in testing for possible benefit in PD, have a lower risk of Parkinson’s.

  • Urge Congress to Safeguard Medicare Funding

    What We Fund: $7.3M for New Cognition Trial, Parkinson’s Protein Measures and More

    The Michael J. Fox Foundation issued 33 new grants in August and September toward new treatments, better ways to measure Parkinson’s and deeper understanding of the disease.

Gloved hand holding research samples.

Be Part of the Answer

You have the power to impact your future and the future of millions living with Parkinson's disease. Explore clinical research participation today.

Join a Study
Michael J. Fox in blue sweater posing for the camera.

Patients First

Our Foundation exists for one reason: to speed breakthroughs patients can feel in their everyday lives.

Read Our Promise
"The question most frequently asked of us is: 'How close are we to a cure for Parkinson’s disease?' With over $800 million in Parkinson's research funded to date, the simplest answer is: closer than ever."
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.